FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to therapeutic double-stranded ribonucleic acids; it can be used in medicine for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome. Double-stranded ribonucleic acids are proposed, containing a combination of a sense chain with an antisense chain, selected from SEQ ID NO: 159 and 160, SEQ ID NO: 141 and 142, SEQ ID NO: 143 and 144, SEQ ID NO: 145 and 146, SEQ ID NO: 147 and 148, SEQ ID NO: 153 and 154.
EFFECT: invention provides for effective suppression of expression of C5 complement component.
27 cl, 6 dwg, 26 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SIRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING NRARP GENE EXPRESSION | 2016 |
|
RU2738971C2 |
| METHODS FOR TREATMENT OF HEPATITIS B INFECTION | 2018 |
|
RU2780021C2 |
| MIRNA STRUCTURES WITH HIGH ACTIVITY AND REDUCED EXPOSURE OUTSIDE THE TARGET | 2016 |
|
RU2788030C2 |
| RNA MOLECULES | 2018 |
|
RU2819868C2 |
| COMPOSITIONS AND METHODS FOR INHIBITION OF PROTEOLYTIC PATH OF ARGININE/N-DEGRON | 2020 |
|
RU2787841C2 |
| RNA MOLECULES CONTAINING NON-CANONICAL BASE PAIRS | 2019 |
|
RU2812710C2 |
| NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD OF PRODUCTION AND USE | 2020 |
|
RU2816898C2 |
| RNA INTERFERENCE-MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION WITH THE USE OF A SMALL INTERFERING NUCLEIC ACID (siNA) | 2011 |
|
RU2745848C2 |
| TREATMENT OF TUMORS OF DISEASES RELATED TO THE GENOM-SUPPRESSOR BY THERAPY OF NATURAL TRANSCRIPT INHIBITION IN ANTI-SIGNIFICANT ORIENTATION REGARDING THIS GENE | 2009 |
|
RU2746478C2 |
| DOUBLE-CHAINED OLIGONUCLEOTIDE SPECIFIC TO CTGF GENE AND COMPOSITION CONTAINING IT FOR PREVENTION AND TREATMENT OF FIBROUS DISEASES AND DISEASES ASSOCIATED WITH RESPIRATORY SYSTEM | 2020 |
|
RU2807108C1 |
